Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Depomed, Inc.
Depomed Initiates Second Phase 3 Trial in Menopausal Hot Flashes
November 8th, 2008
Depomed, Inc. (NASDAQ:DEPO) announced the enrollment and dosing of the first patient in Breeze 2, the second of two pivotal Phase 3 clinical trials in Depomed's registration program for DM-5689 (formerly referred to as Gabapentin GR(R)) for the treatment of menopausal hot flashes. Breeze 1, the first Phase 3 clinical trial, was initiated in September. "I look forward to the results of Depomed's Phase 3 trials for DM-5689 in menopausal hot flashes after having seen Depomed's encouraging Phase 2 results. An effective non-hormonal and non-antidepressant treatment alternative would provide great value to patients and physicians," said Wulf Utian, MD PhD DSc, Executive...
Source: Law & Health Weekly (2008-11-08)
|
